Evidence map›Paper›PMID 32848039›Full record

ArticleJournal of clinical microbiology2020

Evaluation of Cysteine Protease C of Leishmania donovani in Comparison with Glycoprotein 63 and Elongation Factor 1α for Diagnosis of Human Visceral Leishmaniasis and for Posttreatment Follow-Up Response.

Nicky Didwania, Sarfaraz Ahmad Ejazi, Rudra Chhajer, Abdus Sabur, Saumyabrata Mazumder, Mohd Kamran, Raunak Kar, Krishna Pandey, Vidya Nand Ravi Das, Pradeep Das and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. The potential ofMicrobiology spectrum · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Molecular Tracking of theFrontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Nicky DidwaniaInfectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Sarfaraz Ahmad EjaziInfectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Rudra ChhajerInfectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Abdus SaburInfectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Saumyabrata MazumderInfectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Mohd KamranInfectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Raunak KarInfectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
Krishna PandeyDepartment of Clinical Medicine, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Vidya Nand Ravi DasDepartment of Clinical Medicine, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Pradeep DasDepartment of Molecular Biology, Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Mehebubar RahamanDepartment of Tropical Medicine, School of Tropical Medicine, Kolkata, India.
Rama Prosad GoswamiDepartment of Tropical Medicine, School of Tropical Medicine, Kolkata, India.
Nahid AliInfectious Diseases and Immunology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India nali@iicb.res.in.ORCID 0000-0002-6166-3778
Indian Institute of Chemical Biology · INRajendra Memorial Research Institute of Medical Sciences · INIndian Institute of Tropical Meteorology · IN

Funding

Medical Research Council MR/P027989/1
6 · The paper itself

Abstract

Visceral leishmaniasis (VL) is a threat in many developing countries. Much effort has been put to eliminating this disease, for which serodiagnosis remains the mainstay for VL control programs. New and improved antigens as diagnostic candidates are required, though, as the available antigens fail to demonstrate equal optimum performance in all areas of endemicity. Moreover, these diagnoses are dependent on invasive serum sampling. In the current study, we cloned and expressed

Indexed as

Cysteine ProteasesLeishmania donovaniLeishmaniasis, VisceralAntibodies, ProtozoanAntigens, ProtozoanCysteineEnzyme-Linked Immunosorbent AssayFollow-Up StudiesGlycoproteinsHumansPeptide Elongation Factor 1Sensitivity and SpecificityAntibodies, ProtozoanAntigens, ProtozoanCysteineCysteine ProteasesGlycoproteinsPeptide Elongation Factor 1diagnosisimmunologyinfectionleishmaniasisparasitologyrecombinant antigens

Identifiers

PMID32848039
PMCPMC7587114
OpenAlexW3080945095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.